Quality Assured: Bringing Life-Changing Therapies To Patients
By Rob Frater, Laboratory Manager, and Arthur Stevenson, QP Services Manager, Qualified Person, PCI Pharma Services
CDMOs play an essential role in the pharmaceutical industry, supporting companies to deliver products to patients swiftly and efficiently. PCI’s flexibility and agility ensures we are well positioned to assist with any number of challenges that may arise. Biopharmaceutical drug development remains a key trend, demanding specific expertise and capabilities when it comes to Quality Assurance.
As a CDMO, we must provide consistency in approach, reliability in service, flexibility in meeting the varied nature of requirements, and true expertise in the areas contracted to us. A strong focus on identifying any issues and pursuing corrective and preventive action (CAPA) in a timely manner is also of core importance.
In this article, we explore four areas in biologics that appear to be major talking points for our customers, which means they’re also of fundamental importance to PCI.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.